PIK3CA mutations in breast cancer: Reconciling findings from preclinical and clinical data

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Zardavas, Dimitrios ^a   Phillips, Wayne A ^b   Loi, Sherene ^b,c  

^a JULES BORDET INSTITUTE   (Belgium)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; LAPATINIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PROTEIN P53; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE SUBUNIT P110 ALPHA; UNCLASSIFIED DRUG;

ALLELE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL DECISION MAKING; ENZYME ACTIVITY; GENE MUTATION; GENE TARGETING; GENOTYPE; HUMAN; IN VITRO STUDY; INTRADUCTAL CARCINOMA; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DISEASE MODEL; DRUG RESISTANCE; FEMALE; GENETICS; MOUSE; MUTATION; TREATMENT OUTCOME; BREAST CARCINOGENESIS; CANCER ADJUVANT THERAPY; CANCER MODEL; CANCER RESISTANCE; DRUG TARGETING; ENZYME STRUCTURE; GENETIC ASSOCIATION; MOUSE MODEL; PROTEIN DOMAIN; PROTEIN FUNCTION;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84892889279     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3605     Document Type: Review

References (77)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657. 10.1126/science.296.5573.1655, 12040186.
2. COSMIC: Catalogue of somatic mutations in cancer. [http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/].
3. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 2012, 13:195-203. 10.1038/nrm3290, 22358332.
4. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619. 10.1038/nrg1879, 16847462.
5. Amzel LM, Huang C-H, Mandelker D, Lengauer C, Gabelli SB, Vogelstein B. Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer 2008, 8:665-669. 10.1038/nrc2443, 2847604, 18633356.
6. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998, 279:710-714. 10.1126/science.279.5351.710, 9445477.
7. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274. 10.1016/j.cell.2007.06.009, 2756685, 17604717.
8. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S, Duval A, Carneiro F, Machado JC, Hamelin R, Seruca R. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005, 41:1649-1654. 10.1016/j.ejca.2005.04.022, 15994075.
9. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, Kang SY, Park JO, Kang WK, MacConaill L, Kim KM. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 2012, 7:e38892. 10.1371/journal.pone.0038892, 3377730, 22723903.
10. Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 2012, 18:6771-6783. 10.1158/1078-0432.CCR-12-2347, 23136191.
11. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson BS, Riggins GJ. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 2006, 4:709-714. 10.1158/1541-7786.MCR-06-0172, 17050665.
12. Krakstad C, Birkeland E, Seidel D, Kusonmano K, Petersen K, Mjøs S, Hoivik EA, Wik E, Halle MK, Øyan AM, Kalland KH, Werner HM, Trovik J, Salvesen H. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLoS One 2012, 7:e52795. 10.1371/journal.pone.0052795, 3531332, 23300780.
13. Riener M-O, Bawohl M, Clavien P-A, Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 2008, 47:363-367. 10.1002/gcc.20540, 18181165.
14. Qiu W, Schönleben F, Li X, Ho DJ, Close LG, Manolidis S, Bennett BP, Su GH. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006, 12:1441-1446. 10.1158/1078-0432.CCR-05-2173, 1780023, 16533766.
15. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih IM. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009, 174:1597-1601. 10.2353/ajpath.2009.081000, 2671248, 19349352.
16. Kompier LC, Lurkin I, van der Aa MNM, van Rhijn BWG, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010, 5:e13821. 10.1371/journal.pone.0013821, 2972209, 21072204.
17. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Piña V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012, 486:405-409. 10.1038/nature11154, 22722202.
18. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. 10.1038/nature11412, 3465532, 23000897, Cancer Genome Atlas Network.
19. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404. 3428862, 22722201.
20. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004, 64:7678-7681. 10.1158/0008-5472.CAN-04-2933, 15520168.
21. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554. 10.1126/science.1096502, 15016963.
22. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005, 7:561-573. 10.1016/j.ccr.2005.05.014, 15950905.
23. Isakoff SJ. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005, 65:10992-11000. 10.1158/0008-5472.CAN-05-2612, 16322248.
24. Zhao JJ. The oncogenic properties of mutant p110 and p110 phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 2005, 102:18443-18448. 10.1073/pnas.0508988102, 1317954, 16339315.
25. Kang S. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005, 102:802-807. 10.1073/pnas.0408864102, 545580, 15647370.
26. Bader AG. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006, 103:1475-1479. 10.1073/pnas.0510857103, 1360603, 16432179.
27. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008, 105:2652-2657. 10.1073/pnas.0712169105, 2268191, 18268322.
28. Chaussade C, Cho K, Mawson C, Rewcastle GW, Shepherd PR. Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochem Biophys Res Commun 2009, 381:577-581. 10.1016/j.bbrc.2009.02.081, 19233141.
29. Pang H, Flinn R, Patsialou A, Wyckoff J, Roussos ET, Wu H, Pozzuto M, Goswami S, Condeelis JS, Bresnick AR, Segall JE, Backer JM. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res 2009, 69:8868-8876. 10.1158/0008-5472.CAN-09-1968, 2793177, 19903845.
30. Hao Y, Wang C, Cao B, Hirsch BM, Song J, Markowitz SD, Ewing RM, Sedwick D, Liu L, Zheng W, Wang Z. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. Cancer Cell 2013, 23:583-593. 10.1016/j.ccr.2013.03.021, 23643389.
31. Miled N, Yan Y, Hon WC, Perisic O, Zvelebil M, Inbar Y, Schneidman-Duhovny D, Wolfson HJ, Backer JM, Williams RL. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007, 317:239-242. 10.1126/science.1135394, 17626883.
32. Huang C-H, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB, Amzel LM. The structure of a human p110/p85 complex elucidates the effects of oncogenic PI3K mutations. Science 2007, 318:1744-1748. 10.1126/science.1150799, 18079394.
33. Gymnopoulos M, Elsliger M-A, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 2007, 104:5569-5574. 10.1073/pnas.0701005104, 1838453, 17376864.
34. Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart MJ, Joensuu H, Sotiriou C. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 2013, 105:960-967. 10.1093/jnci/djt121, 23739063.
35. Sabine V, Crozier C, Drake C, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea D, Bartlett JMS. PIK3CA mutations are linked to PgR expression: A Tamoxifen Exemestane Adjuvant Multinational (TEAM) pathology study. Cancer Res 2012, 72:S1-S5.
36. Aka JA, Adjo Aka J, Lin S-X. Comparison of functional proteomic analyses of human breast cancer cell lines T47D and MCF7. PLoS One 2012, 7:e31532. 10.1371/journal.pone.0031532, 3286449, 22384035.
37. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402. 10.1016/j.ccr.2007.08.030, 17936563.
38. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2009, 21:255-262.
39. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440. 10.1016/j.ccr.2009.03.020, 19411071.
40. Zardavas D, Fumagalli D, Loi S. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?. Curr Opin Oncol 2012, 24:623-634. 10.1097/CCO.0b013e328358a2b5, 22960556.
41. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008, 68:826-833. 10.1158/0008-5472.CAN-07-2707, 18245484.
42. Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiaer U, Espelund U, Jepsen JS. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res 2006, 16:224-239. 10.1016/j.ghir.2006.06.005, 16893667.
43. Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010, 120:2406-2413. 10.1172/JCI41680, 2898598, 20530877.
44. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010, 107:10208-10213. 10.1073/pnas.0907011107, 2890442, 20479250.
45. Koren S, Bentires-Alj M. Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors. FEBS J 2013, 280:2758-2765. 10.1111/febs.12175, 23384338.
46. Meyer DS, Brinkhaus H, Muller U, Muller M, Cardiff RD, Bentires-Alj M. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res 2011, 71:4344-4351. 10.1158/0008-5472.CAN-10-3827, 21482677.
47. Adams JR, Xu K, Liu JC, Agamez NM, Loch AJ, Wong RG, Wang W, Wright KL, Lane TF, Zacksenhaus E, Egan SE. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res 2011, 71:2706-2717. 10.1158/0008-5472.CAN-10-0738, 21324922.
48. Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. PLoS One 2012, 7:e36924. 10.1371/journal.pone.0036924, 3364244, 22666336.
49. Yuan W, Stawiski E, Janakiraman V, Chan E, Durinck S, Edgar KA, Kljavin NM, Rivers CS, Gnad F, Roose-Girma M, Haverty PM, Fedorowicz G, Heldens S, Soriano RH, Zhang Z, Wallin JJ, Johnson L, Merchant M, Modrusan Z, Stern HM, Seshagiri S. Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 2013, 32:318-326. 10.1038/onc.2012.53, 3550595, 22370636.
50. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, Zhao JJ. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 2011, 17:1116-1120. 10.1038/nm.2402, 3169724, 21822287.
51. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009, 15:5049-5059. 10.1158/1078-0432.CCR-09-0632, 19671852.
52. Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, Driouch K, Fourme E, Lidereau R, Bièche I. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Res 2012, 14:R28. 10.1186/bcr3113, 3496146, 22330809.
53. Pérez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007, 13:3577-3584. 10.1158/1078-0432.CCR-06-1609, 17575221.
54. Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, Tabone E, Puisieux A, Wang Q. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat 2012, 132:29-39. 10.1007/s10549-011-1518-y, 21512767.
55. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen A-S, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820. 10.1056/NEJMoa053028, 16495393.
56. Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Piccart MJ, Joensuu H, Sotiriou C. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 2013, 105:960-967. 10.1093/jnci/djt121, 23739063.
57. Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, Davies S, DeSchryver K, Evans DB, Steinseifer J, Bandaru R, Liu W, Gardner H, Semiglazov V, Watson M, Hunt K, Olson J, Baselga J. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 2010, 119:379-390. 10.1007/s10549-009-0575-y, 2810126, 19844788.
58. Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010, 70:5674-5678. 10.1158/0008-5472.CAN-08-2660, 2905503, 20551053.
59. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091. 10.1158/0008-5472.CAN-07-6854, 2680495, 18676830.
60. Carracedo A, Alimonti A, Pandolfi PP. PTEN level in tumor suppression: how much is too little?. Cancer Res 2011, 71:629-633. 10.1158/0008-5472.CAN-10-2488, 3249925, 21266353.
61. Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 2011, 128:447-456. 10.1007/s10549-011-1572-5, 21594665.
62. Chandarlapaty S, Sakr RA, Giri D, Patil S, Heguy A, Morrow M, Modi S, Norton L, Rosen N, Hudis C, King TA. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 2012, 18:6784-6791. 10.1158/1078-0432.CCR-12-1785, 3525734, 23092874.
63. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010, 177:1647-1656. 10.2353/ajpath.2010.090885, 2947262, 20813970.
64. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008, 68:9221-9230. 10.1158/0008-5472.CAN-08-1740, 2587064, 19010894.
65. Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer 2011, 11:248. 10.1186/1471-2407-11-248, 3141770, 21676217.
66. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119. 10.1056/NEJMoa1113216, 22149875, CLEOPATRA Study Group.
67. Baselga J, Cortes J, Im S-A, Clark E, Kiermaier A, Ross G, Swain SM. Biomarker analyses in CLEOPATRA: a phase III, placebo controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res 2012, 72:S1-S5.
68. Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 2012, 17:69-95. 10.1615/CritRevOncog.v17.i1.60, 22471665.
69. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, DeFeo-Jones D, Huber HE, Rosen N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008, 3:e3065. 10.1371/journal.pone.0003065, 2516933, 18725974.
70. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA, Watson MA, Saporita A, Weber JD, Ellis MJ. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009, 69:3955-3962. 10.1158/0008-5472.CAN-08-4450, 2811393, 19366795.
71. Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, Lee WJ, Rewcastle GW, Denny WA, Singh R, Dickson J, Baguley BC, Shepherd PR. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J 2011, 438:53-62. 10.1042/BJ20110502, 3174055, 21668414.
72. Juric D, Rodon J, Gonzalez-Angulo AM, Burris HA, Bendell J, Berlin JD, Middleton MR, Bootle D, Boehm M, Schmitt A, Rouyrre N, Quadt C, Baselga J. Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: preliminary safety, PK, and efficacy results from the first-in-human study. Cancer Res 2012, 72:CT-01-CT-01.
73. Mayer I, Abramson V, Balko J, Isakoff SJ, Kuba MG, Sanders ME, Forero-Torres A, Yap JT, Van Den Abbeele AD, Li Y, Arteaga CL, Winer E. SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). J Clin Oncol 2012, 30:Abstract 510.
74. Krop IE, Saura C, Ahnert J, Becerra C, Britten C, Isakoff SJ, Demanse D, Hackl W, Quadt C, Silva AP, Burris HA, Abu-Khalaf MM, Baselga J. A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer. J Clin Oncol 2012, 30:Abstract 508.
75. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529. 10.1056/NEJMoa1109653, 22149876.
76. Hortobagyi GN, Piccart MJ, Rugo HS, Burris HA, Campone M, Noguchi S, Perez A, Deleu I, Shtivelband M, Provencher L, Masuda N, Dakhil SR, Anderson I, Chen D, Damask A, Huang A, McDonald R, Taran T, Sahmoud T, Baselga J. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: results from BOLERO-2. 2013 ASCO Annual Meeting. J Clin Oncol 2013, 31:Abstract LBA509.
77. NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer. [http://clinicaltrials.gov/ct2/show/NCT01816594].